via foxbusiness.com
The suit, brought by Connecticut pension funds on behalf of purchasers of Amgen stock, alleged the Thousand Oaks, Calif., company repeatedly reassured investors about the safety of anti-anemia drugs Aranesp and Epogen even as clinical trial data raised concerns that the drugs could harm cancer patients who were taking them. Amgen's statements led to inflated share prices, the suit alleged.
Read more: http://www.foxbusiness.com/news/2013/02/27/us-supreme-court-rejects-amgen-cha...
No comments:
Post a Comment